Period:
Draw Mode:
| Volume | 56,201 |
|
|||||
| News | - | ||||||
| Day High | 1.95 | Low High |
|||||
| Day Low | 1.53 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| BioCardia Inc | BCDA | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.34 | 22.37% | 1.86 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.53 | 1.53 | 1.95 | 1.86 | 1.52 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 284 | 56,201 | $ 1.72 | $ 96,560 | - | 1.2301 - 2.60 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:19:00 | 1 | $ 1.84 | USD |
BioCardia Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 37.61M | 20.22M | 16.73M | $ 64.00k | $ -35.01k | -0.17 | -1,074.25 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | - | 98.30% |
BioCardia News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BCDA Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.75 | 1.95 | 1.52 | 1.62 | 85,637 | 0.11 | 6.29% |
| 1 Month | 2.04 | 2.13 | 1.52 | 1.75 | 44,919 | -0.18 | -8.82% |
| 3 Months | 2.15 | 2.27 | 1.52 | 1.90 | 29,428 | -0.29 | -13.49% |
| 6 Months | 1.79 | 2.60 | 1.52 | 1.98 | 39,560 | 0.07 | 3.91% |
| 1 Year | 1.66 | 2.60 | 1.2301 | 1.86 | 43,895 | 0.20 | 12.05% |
| 3 Years | 4.13 | 8.60 | 1.1001 | 4.03 | 566,233 | -2.27 | -54.96% |
| 5 Years | 5.24 | 8.60 | 1.1001 | 4.05 | 450,404 | -3.38 | -64.5% |
BioCardia Description
| BioCardia Inc is a clinical stage regenerative medicine company. It is developing therapeutics for cardiovascular diseases with large unmet medical needs. The company is developing comprehensive biotherapeutic candidates for cardiac regenerative medicine namely CardiAMP and CardiALLO, with a focus on heart failure resulting from a heart attack. |